Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001650381
Ethics application status
Approved
Date submitted
25/10/2017
Date registered
22/12/2017
Date last updated
16/01/2019
Date data sharing statement initially provided
16/01/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Role of home telemonitoring of lung function using the forced oscillation technique (FOT) in asthma during down-titration of treatment
Scientific title
Role of home telemonitoring of lung function using the forced oscillation technique in predicting exacerbations and control among moderate-severe asthmatics during down-titration of treatment: a pragmatic, observational study
Secondary ID [1] 293199 0
CT­2017­CTN­03229­1 v1
Universal Trial Number (UTN)
U1111-1204-1827
Trial acronym
ASTHMA-HOMEMON
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 305197 0
Condition category
Condition code
Respiratory 304512 304512 0 0
Asthma

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
In a pragmatic, observational study, we will evaluate the ability of day-to-day variations in lung function measured by the forced oscillation technique (FOT), to predict occurrence of exacerbations (primary outcome) and changes in symptom control (secondary outcome) in asthma, during physician-indicated down-titration of treatment according to Australian guidelines.

Potential patients are identified during routine clinic visits (treated as Visit 1) based on their clinical status (well-controlled symptoms and on maximal ICS treatment dose) and consideration for down-titration of treatment by their treating physician according to Australian guidelines. Patients who are eligible for the study will be asked if they are willing to participate in home monitoring, and have their baseline health status, symptoms (ACQ-5) and standard respiratory function (spirometry and lung volumes) data collected as part of their standard clinical assessment.

Patients willing to participate in the study will have a FOT device installed in their homes by a study investigator (a respiratory researcher familiar with FOT), who will train them to make unsupervised FOT self-measurements during a 30-45 minute visit.

Participants will be monitored for an initial (approximate) 8-week baseline period during which existing treatment will be unchanged unless clinically warranted. Following this, physician-indicated step-down of treatment will be initiated, to 50% of the patient’s regular maintenance ICS dose for 8 weeks, with a further 50% step-down or switch from twice- to once-daily treatment after another 8 weeks if clinically indicated, consistent with recommendations in Australian guidelines. For most patients, these reductions in ICS dose will be achieved with commercially available combination ICS/LABA formulations; for patients using separate ICS and LABA inhalers at entry (e.g. those whose ICS is ciclesonide or beclomethasone), the dose reductions will be achieved with commercially available ICS formulations, with the same LABA dose continued. Monitoring will cover a total period of approximately 24 weeks (8 weeks of baseline period + 16 weeks prediction phase). During this time, any treatment decisions/changes will be made solely by the treating physician based on the patient’s clinical need.

Throughout the entire study period, patients will self-record symptoms and FOT once daily in the morning, followed by a PEF measurement, before taking their maintenance treatment. Patients will also have weekly telephone interviews where questionnaire data (ACQ), symptoms and exacerbations will be captured. Details of measurements performed during home monitoring can be found below.

It is expected that patients will come in for further visits for clinical assessment and standard respiratory function testing whenever clinically indicated: prior to the prediction phase (Visit 2, at which treatment step-down is confirmed), midway during the prediction phase (Visit 3, at which need for further treatment step-down is evaluated), and at the end of the study (Visit 4).

Treatment Changes
Should a treating physician deem that a change in treatment is warranted during any phase, e.g. due to loss of control or exacerbations, patients will not need to be withdrawn, but will continue daily monitoring as per usual.

FOT Measurements
FOT home monitoring devices (Resmon Pro DIARY, Restech srl, Milan, Italy) will be set up at the patient’s home at enrolment. The technical specifications for the device have been previously published [Dellaca et al, Physiol Meas (2010) 31:N11–N24]. During measurement, a loudspeaker generates 5-11-19 Hz forced oscillations delivered to the airway opening via an antibacterial filter/mouthpiece assembly. The resulting airway opening pressure and flow are measured and used to calculate respiratory resistance. These can be further partitioned into an inspiratory and expiratory component.

Patients will be instructed to make a 1- to 2-min measurement (for a minimum of 10 technically acceptable breaths) each day during normal breathing whilst seated, wearing a nose clip and with cheeks supported. De-identified FOT data will be uploaded daily via the 4G mobile internet network to encrypted servers, where they will be checked for quality by a research assistant.

PEF Measurements
Following FOT, patients will also monitor their PEF using a digital spirometer using standardised protocol, i.e. highest of 3 blows. Patients who currently make PEF measurements will be asked to use the digital spirometer, and they will be shown how to extract the results for their normal monitoring. Patients who have never made PEF measurements before will be instructed on how to do them during the home visit.

Symptom and Exacerbation Measurements
Daily symptoms will be entered into an electronic diary prior to the FOT measurement via the same device interface. We will use an adaptation of symptom diary used in a recently published trial [Virchow et al, Jama (2016) 315:1715-25], from which the definition of moderate exacerbations was derived. In addition, study personnel will contact the patient weekly to record treatment changes, symptoms (ACQ-5), medications and asthma-related healthcare utilisation, to capture changes in asthma control and/or exacerbations. During this time, patients will continue to see their usual healthcare provider when necessary.

Intervention code [1] 299453 0
Early Detection / Screening
Intervention code [2] 299454 0
Diagnosis / Prognosis
Comparator / control treatment
The patients' own periods of no exacerbations and/or baseline periods serve as their own controls.
Control group
Active

Outcomes
Primary outcome [1] 303755 0
Occurrence of moderate asthma exacerbations.

These will be defined based on ATS/ERS criteria, as operationalised by Virchow et al [Respir Med (2015) 109:547-556], i.e. based on at least one of the following factors:
• Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights or increase of greater than or equal to 0.75 from baseline in daily symptom score on 2 consecutive days
• Increase from baseline in occasions of SABA use on 2 consecutive days of greater than or equal to 4 puffs/day
• Greater than or equal to 20% decrease in PEF from baseline on at least 2 consecutive mornings/evenings
• Visit to the emergency department for asthma treatment not requiring systemic corticosteroids
Timepoint [1] 303755 0
All moderate asthma exacerbations (assessed weekly from daily data) that have occurred at the end of the 24-week study period.
Primary outcome [2] 304123 0
Occurrence of severe asthma exacerbations.

These will be recorded, based on the ATS/ERS criteria of events requiring treatment with systemic corticosteroids for greater than or equal to 3 days, and/or hospitalisation or emergency department visit requiring corticosteroid treatment [Reddel et al, Am J Respir Crit Care Med (2009) 180:59–99].
Timepoint [2] 304123 0
All severe asthma exacerbations (assessed weekly from daily data) that have occurred at the end of the 24-week study period.
Secondary outcome [1] 340084 0
Change in Asthma Control Questionnaire score
Timepoint [1] 340084 0
In weekly intervals over the 24-week trial period
Secondary outcome [2] 340085 0
Change in the variability of inspiratory FOT resistance (R5,insp), obtained from daily measurements recorded by the FOT home monitoring device
Timepoint [2] 340085 0
Variability is assessed from daily data in weekly intervals over the 24-week trial period. Change in the variability is calculated from the week before and week after any prescribed changes in asthma treatment.
Secondary outcome [3] 341035 0
Change in the variability of inspiratory FOT reactance (X5,insp), obtained from daily measurements recorded by the FOT home monitoring device
Timepoint [3] 341035 0
Variability is assessed from daily data in weekly intervals over the 24-week trial period. Change in the variability is calculated from the week before and week after any prescribed changes in asthma treatment.
Secondary outcome [4] 341036 0
Change in the variability of PEF, obtained from daily measurements recorded by the home spirometer device.
Timepoint [4] 341036 0
Variability is assessed from daily data in weekly intervals over the 24-week trial period. Change in the variability is calculated from the week before and week after any prescribed changes in asthma treatment.

Eligibility
Key inclusion criteria
Inclusion Criteria:
• above 18 years of age,
• diagnosis of asthma, confirmed by written report from a physician, and
• receiving maintenance asthma treatment at at least Step 4 (on moderate to high dose of ICS (budesonide >500 mcg/day or fluticasone propionate >200 mcg/day or equivalent and LABA treatment) of Australian guidelines, and
• ACQ-5 score <1.5, consistent with adequate symptom control,

All patients will be eligible if their physician is considering stepping down their treatment, from step 4 (the most commonly prescribed asthma treatment in Australia) to step 3, by reducing their regular maintenance inhaled corticosteroid (ICS) dose by 50%, as recommended by Australian guidelines (see http://www.asthmahandbook.org.au/management/adults/stepped-adjustment/stepping-down).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• any other confounding major disease or condition as deemed appropriate by investigator, determined by review of medical history and/or patient reported medical history, and
• impaired ability to understand instructions or perform FOT unsupervised.

Study design
Purpose
Screening
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
FOT data from the first 8 weeks (baseline phase) will be used to calculate the typical risk profile for each individual patient using the variability and statistical properties of FOT data. Following this, data from the subsequent 16 weeks (prediction phase) will be used in a day-by-day rolling update of the patient’s risk profile and to test predictive value for symptom control changes and occurrence of clinically-defined exacerbations.


Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
4/01/2018
Actual
4/01/2018
Date of last participant enrolment
Anticipated
1/06/2021
Actual
Date of last data collection
Anticipated
31/12/2021
Actual
Sample size
Target
40
Accrual to date
27
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 9243 0
Concord Repatriation Hospital - Concord
Recruitment hospital [2] 9244 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 9245 0
Woolcock Institute of Medical Research - Glebe
Recruitment postcode(s) [1] 17902 0
2139 - Concord
Recruitment postcode(s) [2] 17903 0
2065 - St Leonards
Recruitment postcode(s) [3] 17904 0
2037 - Glebe
Recruitment postcode(s) [4] 17905 0
2139 - Concord Repatriation Hospital
Recruitment postcode(s) [5] 17906 0
2065 - Royal North Shore Hospital
Recruitment postcode(s) [6] 17907 0
2037 - Forest Lodge

Funding & Sponsors
Funding source category [1] 297827 0
Other Collaborative groups
Name [1] 297827 0
Centre of Excellence in Severe Asthma
Country [1] 297827 0
Australia
Funding source category [2] 297831 0
University
Name [2] 297831 0
Sydney Medical School, University of Sydney
Country [2] 297831 0
Australia
Primary sponsor type
Other
Name
Woolcock Institute of Medical Research
Address
431 Glebe Point Road, Glebe NSW 2037
Country
Australia
Secondary sponsor category [1] 297218 0
None
Name [1] 297218 0
Address [1] 297218 0
Country [1] 297218 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298880 0
Sydney Local Health District HREC - CRGH
Ethics committee address [1] 298880 0
Ethics committee country [1] 298880 0
Australia
Date submitted for ethics approval [1] 298880 0
27/06/2017
Approval date [1] 298880 0
04/09/2017
Ethics approval number [1] 298880 0
CH62/6/2017-119

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 78538 0
Dr Cindy Thamrin
Address 78538 0
Woolcock Institute of Medical Research
PO Box M77, Missenden Road NSW 2050
Country 78538 0
Australia
Phone 78538 0
+61 2 9114 0440
Fax 78538 0
Email 78538 0
[email protected]
Contact person for public queries
Name 78539 0
Lucy Williams
Address 78539 0
Woolcock Institute of Medical Research
PO Box M77, Missenden Road NSW 2050
Country 78539 0
Australia
Phone 78539 0
+61 403 753 028
Fax 78539 0
Email 78539 0
[email protected]
Contact person for scientific queries
Name 78540 0
Cindy Thamrin
Address 78540 0
Woolcock Institute of Medical Research
PO Box M77, Missenden Road NSW 2050
Country 78540 0
Australia
Phone 78540 0
+61 2 9114 0440
Fax 78540 0
Email 78540 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Daily lung function and electronic diary symptom data, de-identified.
When will data be available (start and end dates)?
Following publication of the study, for 15 years from completion of study as per Good Clinical Practice.
Available to whom?
To researchers, upon request in writing, stating purpose and type of analyses, if deemed to be non-commercial in nature.
Available for what types of analyses?
For scientific (non-commercial) research purposes, including but not limited to posthoc research questions, meta analyses.
How or where can data be obtained?
File transfer from a secure password-protected server


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.